Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03968809 · ClinicalTrials.gov registry record
Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
A clinical trial, sponsored by Genetesis.
- Completed
- Registry status
- 101
- Enrollment target
NCT03968809: Completed study, sponsored by Genetesis.
NCT03968809 is a clinical trial that has completed, run by Genetesis. The registered enrollment target is 101 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03968809 has completed, sponsored by Genetesis.
- COMPLETED
- Registry status
- 101 participants
- Enrollment target
Study Summary
This single-center clinical trial is designed to evaluate the CardioFlux magnetocardiograph diagnostic imaging system to predict major adverse cardiac events (MACE) in patients referred for evaluation for coronary artery disease.
Primary Outcome
Patient follow up will be performed to find the incidence of coronary revascularization at 30 days and 1 year.
Interventions
- DIAGNOSTIC_TEST CardioFlux Magnetocardiography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2020-06-20 |
What the finished NCT03968809 record still lists
NCT03968809 is an observational study that tracks outcomes without assigning an intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which CardioFlux Magnetocardiography is the first listed.
NCT03968809 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03968809 about?
NCT03968809 is a clinical study titled "Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes". This single-center clinical trial is designed to evaluate the CardioFlux magnetocardiograph diagnostic imaging system to predict major adverse cardiac events (MACE) in patients referred for evaluation for coronary artery disease.
What is the current status of trial NCT03968809?
This trial is currently completed. The enrollment target is 101 participants. The study started on 2019-09-05. Estimated completion is 2020-06-20.
What interventions are being tested in trial NCT03968809?
The interventions under investigation include: CardioFlux Magnetocardiography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03968809?
This trial is sponsored by Genetesis, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI